Welcome to our dedicated page for Tenon Medical news (Ticker: TNON), a resource for investors and traders seeking the latest updates and insights on Tenon Medical stock.
Tenon Medical, Inc. reports developments as a medical device company focused on minimally invasive solutions for sacro-pelvic and sacroiliac joint disorders. Company news centers on the Catamaran System and the SImmetry® and SImmetry®+ SI Joint Fusion Systems, including product clearances, initial clinical use, commercial rollout activity, and intellectual property covering SI joint implant technologies.
Recurring updates also include quarterly and annual financial results, revenue trends from SI joint product sales, capital raises through private placements and convertible notes, and funding uses tied to commercial expansion, product development, clinical studies, working capital, and general corporate purposes.
Summary not available.
Tenon Medical, Inc. (NASDAQ:TNON) announced plans to release its financial results for Q1 2023, concluding on March 31, 2023, after market close on May 9, 2023. A conference call will follow at 4:30 p.m. Eastern Time to discuss the results, including a Q&A session. Investors can join the call via dial-in numbers: 1-888-886-7786 (USA) or 1-416-764-8658 (International). The audio will be available for playback until May 23, 2023. Tenon Medical focuses on the Catamaran™ SI Joint Fusion System, which offers a less invasive approach to treat sacroiliac disorders. The company is set for a national launch of this system, targeting a significant market opportunity.
Tenon Medical (NASDAQ:TNON) reported a transformative year, concluding with a 423% revenue increase in Q4 2022, totaling $277,000, and a full-year revenue of $691,000, up 332%. Surgical procedures using the Catamaran System surged 386% in Q4 and 361% for the year. Despite these gains, the company reported a gross loss of $(207,000) in Q4 and $(641,000) for 2022. Operating losses jumped to $7.9 million in Q4 and $18.7 million for the year, impacted by a $3.6 million charge related to the termination of a national distribution agreement. Cash reserves stood at $8.6 million as of year-end, supporting ongoing operations.
Tennon Medical (NASDAQ:TNON) has successfully treated its first patient in the clinical study for the Catamaran SI Joint Fusion System. Conducted by Dr. Mark H. Stouffer at Zion Surgery Center on November 14, 2022, the study aims to evaluate the long-term effectiveness of this innovative system in addressing sacroiliac joint disorders. Patients will be monitored for pain scores and fusion rates over 24 months. The Catamaran design is expected to enhance patient outcomes by stabilizing the joint and facilitating fusion.
Tenon Medical reported a 197% increase in revenue year-over-year for Q3 2022, totaling $208,000. The company launched its Catamaran SI Joint Fusion System at the North American Spine Society meeting, engaging healthcare professionals with workshops and technical exhibits. Operating losses rose to $3.3 million, with a net loss of $3.2 million, compared to losses of $2.1 million and $2.3 million in Q3 2021. The company's cash reserves stand at $12.5 million, expected to support future growth initiatives.
Tenon Medical, Inc. (NASDAQ:TNON) has announced its participation in two upcoming investment conferences. The Q4 Investor Summit will take place on November 14-15, 2022, with CEO Steven Foster and CFO Steven Van Dick presenting on November 15 at 9:30 a.m. Eastern Time. A webcast of this presentation will be available. The company will also participate in the Benchmark 11th Annual Discovery One-on-One Investor Conference on December 1, 2022. Management will be available for one-on-one meetings, and interested parties can contact investor relations.
Tenon Medical, Inc. announced its plans to release financial results for the third quarter ending September 30, 2022, on November 10, 2022, after market close. Following the release, a conference call will be held at 4:30 p.m. Eastern Time to discuss the results in detail, concluding with a Q&A session. The company is known for its Catamaran SI Joint Fusion System, which aims to address the underserved market in sacroiliac disorders. Interested parties can access the call via dial-in or webcast.
Tenon Medical has received Institutional Review Board (IRB) approval for two post-market clinical studies involving its Catamaran SI Joint Fusion System. This approval enables designated centers to start recruiting patients and aims to evaluate clinical outcomes and radiographic results over 6 to 24 months. The studies focus on patients with sacroiliac joint disorders, assessing pain scores and fusions among other outcomes. Tenon reaffirms its commitment to validating patient outcomes with its innovative titanium fixation device.
Tenon Medical, Inc. (NASDAQ:TNON) is set to launch its innovative Catamaran SI Joint Fusion System at the 37th Annual Meeting of the North American Spine Society (NASS) in Chicago from October 12-15, 2022. The Catamaran is a unique titanium fixation device designed for treating sacroiliac disorders. With a hands-on technical exhibit and expert-led training sessions, the company aims to engage spine specialists. Dr. Michael Chaparro will present his clinical outcomes using the Catamaran on October 13. This launch signifies Tenon's strategic shift to control its distribution and enhance commercial infrastructure.
Tenon Medical has amicably terminated its distribution agreement with SpineSource for the Catamaran SI Joint Fusion System, effective October 6, 2022. This move is intended to support Tenon’s growth and transition towards its own commercial infrastructure. Over the next six months, SpineSource will assist in ensuring a smooth transition. Tenon plans to launch the Catamaran system nationally at the upcoming North American Spine Meeting, aiming for sustainable growth and enhanced shareholder value through direct management of its distribution activities.